Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Jaglowski Samantha M.; Jones Jeffrey A.; Flynn Joseph M.; Andritsos Leslie A.; Maddocks Kami J.; Woyach Jennifer A.; Blum Kristie A.; Greyer Michael R.; Geyer Susan Michelle; Heerema Nyla A.; Lozanski Gerard; Stefanos Mona; Hall Nathan; Nagar Veena; Munneke Brian; West Jamie-Sue; Neuenburg Jutta K.; James Danelle F.; Johnson Amy J.; Byrd John C.

首页> 外文期刊>Clinical lymphoma, myeloma & leukemia >Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

【24h】

Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

机译：肝脏慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL / SLL）组合伊布洛替尼与atumumab组合的活性和耐受性（CLL / SLL）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical lymphoma, myeloma & leukemia》 |2015年第1期|共2页
作者
Jaglowski Samantha M.; Jones Jeffrey A.; Flynn Joseph M.; Andritsos Leslie A.; Maddocks Kami J.; Woyach Jennifer A.; Blum Kristie A.; Greyer Michael R.; Geyer Susan Michelle; Heerema Nyla A.; Lozanski Gerard; Stefanos Mona; Hall Nathan; Nagar Veena; Munneke Brian; West Jamie-Sue; Neuenburg Jutta K.; James Danelle F.; Johnson Amy J.; Byrd John C.;
展开▼
作者单位

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Pharmacyclics Inc Sunnyvale CA USA;

Pharmacyclics Inc Sunnyvale CA USA;

Pharmacyclics Inc Sunnyvale CA USA;

Pharmacyclics Inc Sunnyvale CA USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [J] . Jaglowski Samantha M., Jones Jeffrey A., Flynn Joseph M., Clinical lymphoma, myeloma & leukemia . 2015,第Suppla1期

机译：肝脏慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL / SLL）组合伊布洛替尼与atumumab组合的活性和耐受性（CLL / SLL）
2. Efficacy and safety of ibrutinib in Chinese patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) and hepatitis B virus reactivation: a post-hoc analysis [J] . Yang Shenmiao, Zhu Rong, Feng Yu, Leukemia and lymphoma . 2020,第S1期

机译：伊布洛替尼对中国复发/难治（R / R）慢性淋巴细胞白血病或小淋巴细胞淋巴瘤（CLL / SLL）和乙型肝炎病毒再激活的疗效和安全性：HOC分析
3. Final 5-year updated results from a phase 3 study (HELIOS) of ibrutinib plus bendamustine and rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) [J] . Fraser Graeme, Chanan-Khan Asher, Demirkan Faith, Leukemia and lymphoma . 2020,第S1期

机译：最终5年的更新结果来自Ibrutinib Plus Bendamustine和Rituximab（Br）的第3阶段研究（Helios），患有复发/难治性慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）
4. Chronic Lymphocytic Leukemia (CLL): New Insight on the Pathogenesis of CLL Cell Survival [C] . L. Lagneaux, A. Delforge, M. Dejeneffe, European Haematology Association . 2002

机译：慢性淋巴细胞白血病（CLL）：对CLL细胞生存发病机制的新见解
5. Risk Factors for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Incidence in Postmenopausal Women: A Women's Health Initiative (WHI) Study [D] . Maharry, Kati S. 2016

机译：绝经后妇女慢性淋巴细胞白血病和小淋巴细胞淋巴瘤发生率的危险因素：妇女健康倡议（WHI）研究
6. Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) in Routine Clinical Practice [O] . Heidi D. Finnes, Kari G. Chaffee, Timothy G. Call, -1

机译：常规临床实践中依鲁替尼治疗慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）期间的药物警戒
7. Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Who Have Undergone Prior Allogeneic Stem Cell Transplant [O] . Miklos David B., Coutre Steven, OBrien Susan, 2015

机译：依鲁替尼在异基因干细胞移植后复发/难治性（R / R）慢性淋巴细胞性白血病（CLL）/小淋巴细胞性淋巴瘤（SLL）患者中的安全性和有效性

Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

著录项

相似文献

相关主题

期刊订阅